Denali Therapeutics Inc.
SUBSTITUTED PYRIMIDINES AS LRKK2 INHIBITORS
Last updated:
Abstract:
The present disclosure relates generally to compounds of formula (I) ##STR00001## or a pharmaceutically acceptable salt, prodrug, deuterated analog, tautomer, stereoisomer, or mixture of stereoisomers thereof and their use as LRRK2 inhibitors.
Status:
Application
Type:
Utility
Filling date:
7 Jun 2021
Issue date:
30 Sep 2021